Table 1.

Comparison of clinical characteristics between no-immune-related adverse event (irAE) and irAE groups.

	All	irAE (n = 13)	no-irAE (n = 10)	p Value
V	70 (45–87)	68	73 (45–80)	0.99
Sex
Male	18	9	9	0.33
Female	5	4	1
Histology
Clear cell carcinoma	19	11	8	0.99
Other	4	2	2
Times of CCB therapy
1–2	8	4	4	0.65
3–4	15	9	6
Effect of CCB therapy
PD, SD	9	5	4	0.48
PR, CR	13	8	5
No evaluation	1	0	1

PD: Progression disease, SD: Stable disease, PR: Partial response, CR: Complete response.